Organisation paid for research Program year 2025 Source: CMS Open Payments

Brigham and Womens Physicians Organization

Neither a doctor nor a teaching hospital

Research payments

$469,145

326 payments

Through program year 2025, Brigham and Womens Physicians Organization is reported as receiving $469,145 in research payments, across 326 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $26,647 197
2024 Research $23,125 22
2023 Research $9,339 7
2022 Research $38,799 5
2021 Research $55,320 24
2020 Research $110,201 50
2019 Research $205,715 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Acerta Pharma LLC $170,919 10 payments
  2. Janssen Research & Development, LLC $144,905 52 payments
  3. Boehringer Ingelheim International GmbH $42,332 175 payments
  4. UCB Biosciences Inc. $40,965 4 payments
  5. BeiGene (Suzhou) Co., Ltd. $37,585 21 payments
  6. Eli Lilly and Company $11,675 1 payment
  7. Novo Nordisk AS $7,850 35 payments
  8. Celgene Corporation $6,000 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $3,229 13 payments
  10. BeiGene, Ltd. $1,840 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) $92,785 30 payments
  2. A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia $80,820 2 payments
  3. A Randomized Open label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the Firstline Treatment of Subjects with Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL $49,995 15 payments
  4. A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL $49,650 2 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis $40,965 4 payments
  6. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $39,540 2 payments
  7. A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors $19,900 8 payments
  8. PDE4 Phase III trial in IPF patients $14,435 23 payments
  9. An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China $14,020 11 payments
  10. Monarcher-A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With Or Without Fulvestrant to Standard-Of-Care Chemotherapy of Physicians Choice Plus Trastuzumab in Women With HR+, Her2+ Locally Advanced Or Metastatic Breast Cancer $11,675 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record